Legend Biotech Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Legend Biotech Bundle
Biotech Business Model Canvas: Investor-ready roadmap for value creation and scalable growth
Unlock the full strategic blueprint behind Legend Biotech’s Business Model Canvas — a concise, actionable map of its value propositions, key partners, and revenue drivers. This professional, editable file is perfect for investors, strategists, and founders who need clear, company-specific insights. Purchase the full canvas to benchmark, plan, and scale with confidence.
Partnerships
Global pharma co-development
Strategic alliances with large pharma expand clinical, regulatory, and commercial reach, as Legend’s 2017 collaboration with Janssen (USD 350 million upfront, up to ~USD 2 billion in milestones) provided global regulatory and commercialization scale. Co-development accelerates trials and label expansions while sharing risk and costs. Joint commercialization strengthens market access and post-launch evidence, and structured governance ensures aligned portfolio prioritization.
Academic and clinical centers
Partnerships with leading cancer institutes enabled Legend Biotech’s clinical enrollment and translational research for cilta-cel, approved by the FDA in 2022, and continue to support ongoing registrational and post-marketing studies as of 2024. Access to KOLs refines protocols and endpoints, improving trial efficiency and regulatory dialogue. Real-world evidence generation strengthens payer health-economic cases, while shared biobanking accelerates biomarker discovery.
CDMOs and apheresis networks
CDMOs and apheresis networks extend Legend Biotech’s manufacturing footprint and patient reach, enabling production and collections across multiple geographies; as of 2024 Carvykti (cilta-cel) remains commercially distributed under this model. Standardized apheresis protocols improve starting material quality and reduce turnaround time for vein-to-vein workflows. Surge flexibility with contract partners mitigates demand spikes during launch or label expansions. Quality agreements enforce GMP and chain-of-identity controls across the supply chain.
Regulatory and HTA engagement
Early scientific advice aligns Legend Biotech development with regulatory expectations; CARVYKTI received FDA approval in February 2022, anchoring ongoing dialogue. HTA bodies define evidence requirements for reimbursement and real-world evidence; payer-led managed entry agreements can de-risk adoption. Continuous regulator and HTA engagement speeds submissions and post-approval variations.
- Regulatory: FDA approval Feb 2022
- HTA: informs evidence for reimbursement
- Managed entry: de-risks payer uptake
- Continuous dialogue: accelerates filings/variations
Technology and logistics providers
- Tracking: digital vein-to-vein platforms, 3–6 week TAT
- Cold chain: vapor-phase LN2 < −130C
- Analytics: real-time SPC, predictive maintenance
- Security: HIPAA and 21 CFR Part 11 compliance
USD 350M pharma deal and CDMO/cold-chain partners underpin commercial CAR-T scale (FDA Feb 2022)
Strategic pharma alliances (Janssen deal: USD 350M upfront, up to ~USD 2B), academic/clinical site networks, CDMO/apheresis partners, regulator/HTA engagement and digital cold-chain/analytics partners underpin commercial CARVYKTI scale (FDA approval Feb 2022) and ongoing 2024 registrational/post-marketing activity.
| Metric | Value (2024) |
|---|---|
| FDA approval | Feb 2022 |
| Janssen deal | USD 350M upfront; ~USD 2B milestones |
| Vein-to-vein TAT | 3–6 weeks |
| Cold chain | Vapor-phase LN2 < −130C |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Legend Biotech detailing customer segments, channels, and value propositions across the 9 BMC blocks, reflecting its CAR‑T oncology platform, strategic partnerships, commercialization and R&D model, competitive advantages, risks and investor-ready insights for presentations and funding discussions.
Customizable Excel Spreadsheet
High-level view of Legend Biotech’s business model with editable cells, enabling rapid alignment of R&D, commercialization and partnership strategies while saving hours on formatting.
Activities
Cell therapy R&D
Design and optimization of CAR constructs and cell engineering methods drive Legend Biotech R&D, supporting ciltacabtagene autoleucel (Carvykti) commercialization after FDA approval in 2022. Rigorous preclinical efficacy and safety testing de-risks clinical entry and informs trial design. Platform innovations prioritize durability and safety while IP generation secures competitive positioning.
Clinical development
Execute multi-phase trials across hematologic and select solid tumors via the CARTITUDE program (CARTITUDE-1/2/3/4), leveraging cilta-cel data showing a 97.9% overall response rate in CARTITUDE-1 and FDA approval on February 28, 2022. Expand labels through line extensions and earlier-line studies to broaden indications. Orchestrate global sites, centralized monitoring, and strict data-integrity systems. Patient-centric designs (decentralized visits, home nursing) improve enrollment and outcomes.
GMP manufacturing
Scale GMP autologous processing with stringent QC/QA to support commercial supply of cilta-cel (Carvykti), which has a U.S. list price of about 465,000 per treated patient, driving the need to improve yields and reduce per-patient cost. Optimize cycle time and release testing to shorten vein-to-vein timelines while implementing digital batch records and analytics for real-time deviation control. Validate additional sites and contract partners to add redundancy and capacity for global rollout.
Regulatory and market access
Prepare regulatory submissions, respond to agency queries and meet post-approval commitments for cell therapy products (CARVYKTI received FDA approval in February 2022); build HTA value dossiers and economic models to support cost-effectiveness and budget impact; negotiate list prices, outcomes-based agreements and reimbursement pathways with payers; maintain global compliance and active pharmacovigilance for safety reporting.
- Regulatory filings: FDA approval Feb 2022
- HTA focus: value dossiers & economic models
- Commercial: pricing, outcomes-based contracts
- Compliance: global pharmacovigilance & post-market commitments
Commercialization and medical affairs
Commercialization and medical affairs educate HCPs and referral centers on patient selection and management, coordinate patient services and case management, generate real-world evidence to support uptake and reimbursement, and provide center training, logistics and quality programs; activity intensified following FDA approval in 2022 and global rollout with commercial partners through 2024.
- Educate HCPs/centers on referral and management
- Coordinate patient services & case management
- Generate & disseminate real-world evidence
- Support training, logistics & quality programs
Scale CAR-T autologous manufacturing, preserve CARTITUDE-1 safety/efficacy (ORR 97.9%)
Design and optimize CAR constructs and GMP autologous manufacturing to commercialize cilta-cel (FDA approved Feb 28, 2022), maintain safety/efficacy via preclinical and CARTITUDE trials (CARTITUDE-1 ORR 97.9%), and execute global regulatory, payer negotiations and post-market pharmacovigilance.
| Metric | Value |
|---|---|
| FDA approval | Feb 28, 2022 |
| CARTITUDE-1 ORR | 97.9% |
| US list price | ~465,000 per patient |
Delivered as Displayed
Business Model Canvas
The Business Model Canvas you’re previewing for Legend Biotech is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, fully formatted, and ready to edit. No surprises: what you see is what you’ll download and use.
Resources
Proprietary CAR-T platforms
Legend Biotech’s proprietary CAR-T platforms—validated by the FDA-approved cilta-cel (Carvykti) commercialized since 2022—combine differentiated constructs and manufacturing know-how to enhance efficacy and safety. Modular platform design shortens candidate-to-clinic timelines and supports a growing pipeline. Process IP secures scalable supply chain leverage. Robust clinical and manufacturing data packages substantiate competitive claims.
GMP facilities and equipment
Validated clean rooms, automated systems, and vapor-phase cryo-storage at around −150°C underpin reliable supply of autologous products; multipoint manufacturing sites provide geographic resilience and surge capacity. In-house QC labs enable rapid lot release and trend-based root-cause control. Digital chain-of-identity and electronic batch records preserve traceability and regulatory compliance across the network.
Clinical and regulatory expertise
Experienced clinical and regulatory teams at Legend steer complex study designs—CARTITUDE-1 enrolled 97 patients—through global filings, enabling FDA approval in 2022. Longstanding agency relationships help streamline reviews and label discussions. Cross-functional program leadership actively manages development and safety risk while medical affairs translates trial science into clinical practice and KOL engagement.
Data assets and analytics
Clinical, manufacturing, and real‑world datasets (CARTITUDE‑1 n=97) guide product and process optimization; CARVYKTI received FDA approval in 2022, enabling post‑approval RWD flows. Predictive models improve scheduling and yields in commercial manufacturing. Safety databases and pharmacovigilance since 2022 support signal detection. Secure, GMP‑aligned platforms protect privacy and data integrity.
- CARTITUDE‑1 n=97
- FDA approval 2022
- Predictive models for scheduling/yield
- Post‑approval safety surveillance
- GMP‑grade secure platforms
Strategic partnerships and capital
Legend Biotech leverages strategic partnerships and capital to access funding, manufacturing capabilities and Janssen’s global commercial reach; the 2017 Janssen collaboration included a $350 million upfront payment and culminated in FDA approval of Carvykti in February 2022, validating the model. Milestone payments de-risk near-term cash needs while long-horizon investor support sustains development of CAR-T programs; governance clauses align partner priorities and value realization.
- Alliances: funding, capabilities, market reach
- 2017 Janssen deal: $350M upfront
- Regulatory milestone: Carvykti FDA approval Feb 2022
- Milestones reduce cash burn; governance aligns incentives
FDA‑approved cilta‑cel platform, GMP cryo manufacturing and 2017 Janssen alliance
Legend’s core resources: FDA‑approved CARVYKTI (cilta‑cel) platform, GMP manufacturing (cryo −150°C, automated cleanrooms), clinical/regulatory teams with CARTITUDE‑1 (n=97) and post‑approval safety systems; 2017 Janssen alliance ($350M upfront) provides global commercial reach and milestone funding.
| Item | Fact |
|---|---|
| CARTITUDE‑1 | n=97 |
| FDA approval | 2022 |
| Janssen deal | $350M upfront (2017) |
Value Propositions
Transformative patient outcomes
CAR-T therapies deliver deep responses and prolonged survival in hard-to-treat cancers—ciltacabtagene autoleucel showed an overall response rate of 97% and stringent complete response of 67% in CARTITUDE-1. A one-time infusion model can markedly reduce long-term treatment burden versus chronic regimens. Addressing high unmet need produces meaningful clinical impact and a growing evidence base that supports clinician and payer adoption.
Personalized cell therapies
Autologous cell therapies are manufactured from each patient’s cells and tailored to individual tumor antigen profiles, improving target engagement. In pivotal CARTITUDE-1 data used for FDA approval in 2022, ciltacabtagene autoleucel achieved a 97% overall response rate, illustrating enhanced efficacy and durability. Strict GMP manufacturing controls and chain-of-identity preserve cell quality and potency. Customization differentiates these therapies from off-the-shelf alternatives in efficacy and patient fit.
Expanding indications and lines
Legend Biotech (NASDAQ: LEGN) advances a pipeline targeting multiple hematologic malignancies and exploring solid tumors, anchored by FDA-approved ciltacabtagene autoleucel (Carvykti) for adult multiple myeloma after four or more prior lines (approval 2022). Ongoing CARTITUDE trials (including CARTITUDE-4, -5, -6) test earlier-line use to broaden eligible populations; label expansions would materially increase patient access and commercial value while continuous innovation sustains growth.
Reliable vein-to-vein operations
- Integrated logistics: minimizes turnaround and loss
- Real-time tracking: improves transparency for centers/patients
- Redundancy: secures supply continuity
- Consistency: strengthens provider confidence
Health-economic value
One-time BCMA CAR-T (Carvykti list price reported at $465,000) can offset cumulative chronic myeloma therapy costs that often total several hundred thousand dollars annually, reducing lifetime drug spend versus continuous regimens. Outcomes-based contracts increasingly align payment with durability of response, de-risking payer spend. Fewer hospitalizations and less supportive care after durable remissions lower system burden and total cost of care. Robust health-economic dossiers support favorable reimbursement decisions in 2024.
- Price tag: $465,000 per infusion
- Chronic care: drug costs often $200k–$300k/year
- Value: reduced hospital days and supportive care needs
- Payer approach: outcomes-based contracts to align price with benefit
ciltacabtagene autoleucel ORR 97% sCR 67%
CAR-T ciltacabtagene autoleucel achieved ORR 97% and sCR 67% in CARTITUDE-1; FDA approval 2022.
One-time infusion (list price $465,000) reduces chronic therapy burden; outcomes-based contracts and 2024 HE dossiers support reimbursement.
Integrated logistics and Janssen commercialization (by 2024) plus ongoing CARTITUDE-4/5/6 expand access and commercial upside.
| Metric | Value | Source/Year |
|---|---|---|
| ORR | 97% | CARTITUDE-1/2021 |
| sCR | 67% | CARTITUDE-1/2021 |
| List price | $465,000 | 2024 reports |
| Commercial partner | Janssen | Commercialized by 2024 |
Customer Relationships
KOL and center partnerships
Legend Biotech’s KOL and center partnerships—built through the Janssen collaboration initiated in 2017 and FDA approval of cilta‑cel in 2022—drive ongoing clinician collaboration that shapes real‑world practice. Advisory boards of leading clinicians guide evidence generation and trial design. Center enablement programs strengthen referral pathways and operational readiness. Joint co‑authored publications bolster clinical credibility.
Dedicated provider support
Field teams assist with onboarding, training, and case management to ensure timely CAR-T delivery and adherence at treatment centers. 24/7 medical information lines provide continuous guidance on safety and administration. Site coordinators streamline scheduling and documentation to reduce infusion delays. Feedback loops established in 2024 drive iterative process improvements across provider networks.
Patient and caregiver services
Patient and caregiver services streamline navigation to simplify access and logistics for Legend Biotech's CAR-T therapy approved in 2022. Financial counseling and co-pay assistance reduce affordability barriers for eligible patients. Tailored education materials prepare patients and caregivers for the treatment journey. Structured follow-up programs enhance adherence to post-infusion monitoring and long-term care.
Payer and HTA engagement
Legend Biotech maintains active payer and HTA engagement with regular evidence updates to support value assessment, leveraging the 2024 U.S. list price benchmark for Carvykti at 465,000 USD to frame cost-effectiveness discussions. Contracting exploration includes outcomes-based agreements and budget impact tools to model payer affordability, while joint data plans define real-world evidence needs for long-term durability and safety.
- Regular evidence updates: cost-effectiveness and durability data
- Outcomes-based contracting: risk-sharing pilots
- Budget impact tools: payer affordability modeling
- Joint data plans: RWE generation and HTA alignment
Post-market safety and outcomes
Pharmacovigilance ensures ongoing risk management for ciltacabtagene autoleucel (Carvykti), approved in 2022, while CARTITUDE and CIBMTR registries collect long-term effectiveness and safety data through 2024; transparent communication of these findings builds patient and clinician trust and the resulting real-world insights feed lifecycle management and label updates.
- Pharmacovigilance: continuous SAE tracking
- Registries: CARTITUDE/CIBMTR long-term outcomes
- Transparency: regular safety updates
- Lifecycle: RWE informs label and indications
Clinician partnerships and KOL-led evidence power CAR-T access, outcomes-based payer deals
Legend Biotech sustains clinician partnerships from the 2017 Janssen collaboration and 2022 cilta‑cel approval to drive KOL-led evidence generation and center enablement. Field teams, 24/7 medical support and patient navigation services ensure timely CAR‑T delivery and post‑infusion follow‑up. Active payer engagement uses the 2024 U.S. list price benchmark of 465,000 USD to support value and outcomes-based contracting.
| Metric | Value |
|---|---|
| Approval | 2022 |
| List price (U.S.) | 465,000 USD (2024) |
| Partner start | Janssen 2017 |
| Registries | CARTITUDE, CIBMTR (through 2024) |
Channels
Authorized treatment centers
Direct engagement with over 150 certified hospitals worldwide as of 2024 enables timely delivery of cilta‑cel; referral networks and logistics coordination reduced mean infusion turnaround in pilots by weeks. The center‑of‑excellence model concentrates multidisciplinary expertise, supporting complex patient selection and management. On‑site training programs—delivered to 1,200+ clinicians in 2024—maintain procedure quality, while formal accreditation pathways assure protocol consistency and regulatory compliance.
Specialty distribution and logistics
Coordinated apheresis, cryo-shipping, and patient returns preserve cell integrity for CAR-T therapies; Carvykti received US approval in Feb 2022, driving scale-up of these logistics. Integrated scheduling reduces manufacturing and treatment delays, while real-time inventory visibility improves planning and lot allocation. Strategic logistics partners extend Legend Biotech’s global reach into multiple regions by 2024.
Medical conferences and publications
Peer-reviewed data drives adoption for cell therapies, exemplified by CARVYKTI (ciltacabtagene autoleucel) FDA approval in 2022 and subsequent pivotal publications. Congress presentations (ASH attracts over 20,000 attendees) expand clinician awareness and visibility. Sponsored symposia and training programs disseminate best practices, while KOL endorsements accelerate hospital and payer uptake.
Digital provider portals
Digital provider portals for Legend Biotech (NASDAQ: LEGN) support online referral management, treatment status tracking, and documentation for ciltacabtagene autoleucel (Carvykti) commercialization with Janssen; secure messaging accelerates issue resolution and care coordination, while embedded analytics monitor site performance and protocol adherence.
- Online referrals, status, docs
- Secure messaging for faster issue resolution
- Analytics for site performance and compliance
- API integrations to cut administrative tasks
Payer and policymaker forums
Payer and policymaker forums host formal value discussions through scheduled reviews and bilateral meetings, where dossiers and health economic models are submitted via established HTA channels for assessment. Collaborative pilot programs with payers test innovative contracting and outcomes-based arrangements to align pricing with real-world performance. Consensus-building across these forums supports coverage decisions and formulary placement for Legend Biotech therapies.
- Formal reviews and bilateral meetings
- Dossiers and HE models via HTA channels
- Pilot contracts and consensus-driven coverage
150 certified hospitals and 1,200+ clinicians accelerate cilta-cel infusion turnaround
Direct engagement with 150 certified hospitals and 1,200+ clinicians trained in 2024 enabled timely cilta‑cel delivery; pilot programs cut mean infusion turnaround by weeks. Carvykti FDA approval Feb 2022 and ASH visibility (≈20,000 attendees) drove adoption and payer dialogues. Digital portals and logistics partners scaled global reach into multiple regions by 2024.
| Metric | Value |
|---|---|
| Certified hospitals (2024) | 150 |
| Clinicians trained (2024) | 1,200+ |
| FDA approval | Feb 2022 |
| ASH attendance | ~20,000 |
Customer Segments
Centers of excellence
In 2024 tertiary hospitals with dedicated cell therapy units deliver most CAR-T treatments, serving as primary treatment hubs. High-volume sites drive initial adoption and scale-up of new therapies. They require robust training, on-site proctoring and supply-chain support. These centers shape regional referral networks and patient flow into community oncology practices.
Hematologists and oncologists
Hematologists and oncologists identify and refer eligible multiple myeloma patients for CAR-T, with Carvykti (ciltacabtagene autoleucel) FDA-approved in 2022 driving initial commercial uptake. Clinical confidence—shaped by peer-reviewed efficacy/safety data and real-world outcomes—directly determines referral rates. Education on toxicity management and logistics is critical for adoption and reimbursement. Key opinion leaders within societies such as ASH (>25,000 members in 2024) shape community practice.
Eligible cancer patients
Eligible cancer patients, primarily those with relapsed/refractory hematologic malignancies such as multiple myeloma, seek durable, potentially curative CAR-T options; Carvykti (ciltacabtagene autoleucel) received FDA approval in February 2022. Patients prioritize long-term outcomes and coordinated logistics support for manufacturing, infusion and follow-up. Equity gaps and payer access barriers persist, while advocacy groups like the International Myeloma Foundation amplify patient needs.
Payers and health systems
Payers and health systems evaluate value and budget impact; contracting governs access and site-of-care reimbursement. Outcomes data — CARTITUDE-1 reported 97% overall response rate with deep, durable responses — underpins coverage and utilization decisions in 2024. System partnerships enable scalable delivery through center-of-excellence networks.
- value assessment
- contracting/access
- outcomes-driven coverage
- system partnerships/scalability
Research collaborators
Research collaborators from academia and consortia drive science and trials for Legend Biotech, contributing to the multicenter CARTITUDE program (multiple global studies) that accelerated cilta‑cel development after FDA approval in 2022; shared IP and data-sharing agreements in 2024 supported platform studies to expand indications and speed enrollment across international networks.
- academia: multicenter CARTITUDE trials
- shared IP/data: platform study enablement
- expanded indications: platform studies 2024
- multicenter networks: faster enrollment/global sites
Tertiary cell‑therapy hubs, KOL influence and payer outcomes contracting drive access
Tertiary hospitals with cell‑therapy units are primary treatment hubs; high‑volume sites drive scale. Hematologist/oncologist referrals hinge on CARVYKTI efficacy/safety (FDA approved Feb 2022) and education; ASH membership >25,000 (2024) shapes KOL influence. CARTITUDE‑1 showed 97% ORR. Payers demand outcomes-driven value and contracting for center networks.
| Segment | 2024 metric | Key need |
|---|---|---|
| Tertiary hospitals | High‑volume centers | Training/supply chain |
| Physicians | ASH >25,000 | Data/education |
| Patients | Cilta‑cel approved 2022 | Access/logistics |
| Payers | Outcomes-driven | Value contracting |
Cost Structure
R&D and clinical trials
Discovery, preclinical and multi‑phase studies demand significant spend, often $100–400M per asset pre‑approval; complex adaptive or decentralized designs can raise monitoring costs by 20–40%; biomarker development and analytics typically add 5–15% to trial budgets; global programs increase site and regulatory outlays, with Phase III oncology trials commonly costing $50–150M across regions.
Manufacturing and quality
GMP facilities, specialized equipment and single‑use consumables drive over 50% of COGS for autologous CAR‑T platforms like Legend Biotech. Skilled labor and intensive QC (commonly $50k–$150k per batch) are major line items, with bioprocess technician wages typically $55k–$75k. Yield losses and batch failures (commonly 5–15%) materially raise per‑dose cost, while validation and tech transfers add multi‑million dollar overheads during scale‑up.
Logistics and cold chain
Cryogenic shipping, tracking and storage for autologous CAR‑T operations was about $3,000–7,000 per patient in 2024; apheresis coordination and scheduling add roughly $1,000–2,000 per collection. Built‑in redundancy (backup freezers, dual shippers, extra runs) raises fixed logistics overhead by ~15–25%, while insurance and risk‑management programs commonly cost $0.5–1.5M annually for mid‑sized programs.
Commercial and medical affairs
Commercial and medical affairs require sustained investment in field teams, education, and evidence dissemination to support CAR-T adoption and safety monitoring in 2024.
Center enablement programs and hub support add ongoing operational costs; post-marketing studies and registries continue to generate real-world evidence through 2024.
Market access and contracting efforts persist, driving payer engagement, utilization management, and rebate/coverage negotiations.
- Field teams: ongoing deployment
- Education: continuous spending
- Center enablement: support costs
- Post-marketing studies: active
- Market access: persistent effort
Partnership and compliance
Milestone, royalty, and profit-share obligations from the Janssen partnership in 2024 materially compress Legend Biotech margins; payouts tied to product launches and sales trajectories remain a primary cost driver. Ongoing legal, IP maintenance, and audit expenses protect assets and compliance; data security and HIPAA/GDPR-aligned controls are critical given patient data volumes. Corporate functions (finance, HR, manufacturing oversight) sustain scaling and regulatory reporting.
- 2024: partnership-driven payouts are a leading margin pressure
- Legal/IP/audit: continual, non-discretionary spend
- Data security: mandatory investment for patient data compliance
- Corporate ops: fixed overheads enabling commercialization
High R&D and >50% COGS plus QC/logistics drive margin compression in 2024
R&D per asset $100–400M; COGS >50% for autologous CAR‑T; QC/validation $50k–$150k per batch; logistics $3k–$7k per patient; Janssen partnership milestones materially compress margins in 2024.
| Cost item | 2024 estimate |
|---|---|
| R&D per asset | $100–400M |
| COGS | >50% |
| QC/batch | $50k–150k |
| Logistics/patient | $3k–7k |
| Partnership payouts | Material margin pressure |
Revenue Streams
Product sales
Commercial sales of Carvykti (ciltacabtagene autoleucel) drive Legend Biotech’s core revenue, leveraging its FDA approval in 2022. By 2024 geographic expansion into additional markets increased treatment volumes. Ongoing filings for earlier-line indications widen the addressable patient population. Pricing strategies continue to reflect demonstrated clinical value and durability of response.
Collaboration milestones
Development and regulatory milestones deliver non-dilutive cash flow tied to IND, MAA/BLA and approval events, providing upfront and staged payments that de-risk R&D spend. Structured payments align partner incentives with progress, while co-commercial triggers unlock launch fees and shared revenue at commercialization. Risk-sharing provisions in collaborations improve capital efficiency by transferring late-stage costs and tying larger payouts to successful clinical and regulatory outcomes.
Profit-share and royalties
Co-development agreements with Janssen and other partners produce regional profit splits, with Legend receiving profit-share where commercialization rights are shared.
Royalties accrue on partnered sales of therapies like ciltacabtagene autoleucel, with payments varying by geography and indication under tiered contractual terms.
Terms differ by country and therapeutic indication, creating staggered revenue recognition and exposure to local market dynamics.
Durable revenue potential scales with market growth in multiple myeloma CAR-T adoption and expanded indications.
R&D funding and grants
R&D funding and grants enable Legend Biotech to advance its CAR-T pipeline with partners and public programs that share costs and expertise, while grants de-risk early innovation and validate preclinical targets. Consortia funding accelerates platform technology development across indications, and non-dilutive capital from grants and public support extends runway without equity dilution.
- Partners/public programs: cost- and expertise-share
- Grants: de-risk preclinical work
- Consortia: platform scale-up
- Non-dilutive capital: extends runway
Manufacturing and services
Manufacturing and services revenue for Legend Biotech can include fee-for-service and tech-transfer fees, supplemented by training and accreditation programs that generate incremental income; by 2024 there are five approved CAR-T therapies globally, underscoring demand for outsourced manufacturing and training. Companion-diagnostic partnerships and data collaborations offer additional royalty and licensing streams tied to clinical and real-world datasets.
- fee-for-service/tech-transfer
- training & accreditation
- companion diagnostics partnerships
- data licensing/collaborations
Commercial CAR-T sales fuel primary revenue; partnerships and manufacturing diversify income
Commercial sales of Carvykti remain Legend Biotech’s primary revenue source following FDA approval in 2022, supported by geographic expansion in 2024. Partner milestones and royalties provide staged non-dilutive cash tied to development and approvals. Manufacturing, services, diagnostics and data licensing add diversified fee and royalty income. Global CAR-T market saw five approved CAR-T therapies by 2024.
| Revenue Stream | 2024 metric | Notes |
|---|---|---|
| Commercial sales | Carvykti primary | FDA approval 2022; expanded markets 2024 |
| Partner milestones/royalties | Staged payments | Tied to IND/MAA/BLA events |
| Manufacturing/services | Fee/licensing | Training, tech transfer, diagnostics/data |
| Market context | 5 approved CAR-Ts | Global count in 2024 |